Shasun Pharma acquires global rights of Ibuprofen 12 hour extended release OTC

05 May 2014 Evaluate

Shasun Pharmaceuticals, Chennai, India an integrated pharmaceutical company through its wholly owned subsidiary, SVADS Holdings, Switzerland (SVADS) has acquired the global rights from ScolrPharma, USA (Scolr), to develop and commercialize Ibuprofen 12 hour Extended Release OTC tablets (Asset) as well as the associated Controlled Release Technology (CDT) along with global rights of Nuprin trademark, a well known brand in Analgesics. The Asset, having completed a successful Phase III in the US is a differentiated long acting NSAIDS in the Multi Billion Dollar global OTC analgesic market.

Shasun is the world's leading, vertically integrated manufacturer of Ibuprofen and its Derivatives, from actives to formulated packaged products for both the Rx and OTC markets. This acquisition complements Shasun's strategy to expand its range of NSAIDS products through novel, safe and efficacious delivery technologies including transdermal applications across its Ibuprofen franchise.

Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R&D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.

Peers
Company Name CMP
Sun Pharma Inds. 1511.00
Dr. Reddys Lab 6225.05
Cipla 1410.85
Zydus Lifesciences 956.00
Lupin 1655.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.